Spectral AI launches DeepView clinical study to support FDA label expansion for head, hands and feet burns
MDAI•Spectral AI launched a clinical study to support expanding DeepView’s FDA-cleared burn label to head, hand and foot burns; the first site initiation visit was completed at Pinderfields Hospital in the UK, allowing patient enrollment to begin.
1. Study begins
The study is designed to generate evidence for a future label expansion submission and support broader use in anatomically complex burn areas. No clinical results have been presented.
